je.st
news
Tag: pharma
Zosano Pharma raises $50M after IPO hits target
2015-01-27 23:58:05| Biotech - Topix.net
Fremont-based Zosano Pharma, led by CEO Vikram Lamba, raised $50 million in an IPO that priced in the middle of its target range on Tuesday. The company's stock rose slightly in its Nasdaq debut.
Insight: Big Pharma faces up to new price pressure from aggressive insurers
2015-01-15 08:10:55| Biotech - Topix.net
The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P. Morgan Healthcare conference in San Francisco.
Tags: price
big
pressure
insight
Zosano Pharma revives IPO plan with much lower $41.4M target
2015-01-12 19:17:03| Biotech - Topix.net
Zosano Pharma, led by CEO Vikram Lamba, has filed to raise up to $41.4 million in an IPO this month. Zosano Pharma, which is developing a patch that treats osteoporosis, filed new plans to go ahead with an IPO that it postponed last summer.
Shire to buy New Jersey-based NPS Pharma is $5.2B deal
2015-01-11 19:19:23| Biotech - Topix.net
Less than two months after announcing its U.S. headquarters will be in Massachusetts, Shire Pharmaceuticals is buying a New Jersey-based maker of gastrointestinal drugs, NPS Pharma for $5.2 billion. The purchase price represents a 51 percent premium to the share price of NPS when reports of the pending deal first emerged on Dec. 16, and is 9 percent higher than it's stock as of Friday's close.
Valeant Pharma projects double-digit growth in sales, earnings per share in 2015
2015-01-08 17:21:17| Biotech - Topix.net
Valeant Pharmaceuticals International Inc. says it plans to focus on small to medium-sized acquisitions from privately owned companies in 2015 following an unsuccessful attempt to take over California-based Allergan. The Quebec-based company told analysts that it believes its blockbuster bid for the maker of Botox would have been successful if a higher bid hadn't emerged from Actavis, which agreed to pay US$66 billion in cash and stock.
Tags: share
sales
growth
projects
Sites : [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] next »